Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib-containing Regimens in Advanced HER2-positive Breast Cancer
NCT07600164Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2031
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 4 trial of pyrotinib, trastuzumab rezetecan in HER2-positive breast cancer, sponsored by Peking University People's Hospital. Started Jul 2026; status: recruiting.
02
Drugs
pyrotinibtrastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07600164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600164.